The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey | Annals of Hematology
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey | Annals of Hematology
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey | Annals of Hematology,36KB,Prediction of the Number of Patients Infected with COVID-19 Based on Rolling Grey Verhulst Models,57KB,Nano-biochar as a potential amendment for metal(loid) remediation: Implications for soil quality improvement and stress alleviation - ScienceDirect